Alia Therapeutics
MILAN, ITALY / ACCESSWIRE / May 9, 2023 / Alia Therapeutics, a Trento-based start-up specializing in innovative treatments for rare genetic diseases through next-generation gene editing technology, announced the appointment of Adel Nada as an independent member of the Board of Directors.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Adel Nada is Co-founder and Chief Executive Officer of GentiBio, a biotherapeutics company that is developing engineered regulatory T cells (Tregs) programmed to treat autoimmune and inflammatory diseases. Prior to joining GentiBio, Adel was the Chief Medical Officer of Casebia Therapeutics, where he worked on advancing engineered regulatory T cell therapeutics.
Over the past 15 years, he has successfully led translational and immunology programs for experimental and approved therapies, spanning small and large molecules, as well as engineered immune cell products.
Paola Pozzi, Partner at Sofinnova Partners and a member of Alia's Board of Directors, said: "Adel's experience and knowledge of the field will help guide Alia towards the next stage in its development. We feel very fortunate to have such an esteemed leader join our Board of Directors."
Adel Nada, Independent Board Director of Alia, said: "I'm delighted to have been invited to join the board of such a compelling biotech with a very differentiated genome editing platform. I look forward to advancing Alia's platforms and pipeline to enable novel, tailored gene editing strategies that have the potential to overcome current limitations of genome editing and bring more therapies to patients with underserved and currently untreatable diseases and conditions."
Letizia Goretti, Chief Executive Officer of Alia, said: "Adel's experience in biotech is both broad and deep. We are really excited to partner with him as Alia's growth accelerates."
Adel received his medical degree from Alexandria University in Egypt and his master's degree in clinical research from the Pharmacology Dept. at Rush University in Chicago, where he also held an academic position and practiced for 10 years in affiliated hospitals.
About Alia Therapeutics
Alia Therapeutics is an Italian biotech start-up whose mission is to develop innovative treatments for incurable genetic diseases using gene editing technology. The company was founded in October 2018 by Anna Cereseto and a group of researchers from CIBIO, the biotech department of the University of Trento, who discovered the core CRISPR technologies exploited by the start-up. Read more at aliatherapeutics.com
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com
For more information about Sofinnova Telethon, visit https://sofinnovapartners.com/strategy/telethon
Contact
Letizia Goretti
CEO, Alia Therapeutics
info@aliatx.com
SOURCE: Alia Therapeutics
View source version on accesswire.com:
https://www.accesswire.com/753506/Alia-Therapeutics-appoints-Adel-Nada-as-Independent-Board-Director
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
New GTDC Report Highlights Effective Methods for Building Optimal Channel Strategies2.12.2025 15:00:00 CET | Press release
TAMPA, FL / ACCESS Newswire / December 2, 2025 / The Global Technology Distribution Council (GTDC) has released a groundbreaking new industry study titled "Building the Optimal Distribution Strategy." This comprehensive guide provides insights and valuable best practices for evaluating market and channel coverage needs and determining which types of distributors provide the best fit for technology suppliers. Former global channel chief and partner route to market specialist Donna Grothjan led the development of this member-inspired GTDC project, adding her personal knowledge and experience creating and managing distribution strategies, as well as gathering and sharing insight from respected industry peers and subject matter experts. Distribution remains the most cost-effective route-to-market for technology suppliers. That value is rising rapidly in the cloud era as emerging and legacy vendors look to scale sales, support and other operations around these virtual offerings without requ
GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases2.12.2025 06:00:00 CET | Press release
Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF penetration in healthy elderly volunteers, supporting its advancement into further clinical development for Alzheimer's and other neurodegenerative diseases. ANKARA, TR / ACCESS Newswire / December 2, 2025 / GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, has announced new positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class, novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) in San Diego, CA (United States) today. SUL-238 was originally discovered by Sulfateq and has since been further developed through a collaborative effort of Sulfateq and GEN as a novel therapeutic in neurodegenerative diseases. This Phase 1 randomized, d
TheaMou by Theo Announces Global Revival of the Original Olympic Games and Operation PAME BROSTA at Athens Fashion Week26.11.2025 19:00:00 CET | Press release
TheaMou Ignites Athens Fashion Week with a Goddess-Warrior Revival Rooted in Ancient Greece ATHENS, GREECE / ACCESS Newswire / November 26, 2025 / TheaMou by Theo ("My Goddess" in Greek), the creative umbrella uniting MeaDea by Theo, Iellele by Theo, MiDiosa by Theo, and aligned cultural initiatives, presented its Ancient Greek Goddess & Warrior Collection at Athens Fashion Week on November 14th, 2025. Founder, Sam Stathis, used the Athens Fashion Week stage to officially launch operation PAME BROSTA (Moving forward in Greek) and announce the global revival of the ORIGINAL OLYMPIC GAMES.Sam Stathis with Olympic Angels at Athens Fashion Week Sam Stathis with Olympic Angels and TheaMou by MeaDea models at Athens Fashion Week Three Olympic Angels by Theo, each a crowned national beauty queen (Miss Greece-Star Hellas, Stella Mihailidou, Miss Italia, Federica Rizza, and Miss Netherlands, Elize DeJong), opened the runway show, symbolizing the revival of the True Flame of Greece through divin
Clean Air Metals Files PEA Technical Report for the Thunder Bay North Critical Minerals Project24.11.2025 13:00:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / November 24, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) is pleased to announce that it has filed the Preliminary Economic Assessment (PEA) and updated resource that was completed for its Thunder Bay PGE-Cu-Ni Project near Thunder Bay, Ontario, Canada. The results of the PEA and resource were previously disclosed in the Company's news release dated October 9th, 2025. The PEA outlines an 11-year mine life (+ 2 years of pre-production activities) producing 2,500 tonnes per day from a near-surface, ramp-access underground operation. The report is available under the Company's profile at www.Sedarplus.ca and will be available on the Company's website at www.cleanairmetals.ca. All figures are in Canadian Dollars, unless specified otherwise. Highlights The project has a $219.4M1 pre-tax NPV8 against a project capital cost of $89.5M. After-tax NPV of $157.5M The pre-tax internal rate of return (IRR) is
Capital.com Strengthens European Operations with Expanded Customer Service Hub in Bulgaria24.11.2025 09:00:00 CET | Press release
Reports trading volumes of $744 billion in Q3 2025 SOFIA, BG / ACCESS Newswire / November 24, 2025 / Capital.com, the high-growth trading platform and fintech group, today announced the expansion of its operations in Bulgaria with the opening of a new office at Sofia's Office X Business Garden and a 51% increase in local headcount over the past year. This development aligns with the company's strategy to build specialised centres of excellence across key functions, with Bulgaria leading the way in customer service. Building on its established presence in Sofia and complementing its technology hub in Poland, Capital.com plans to invest up to €5 million into its operational infrastructure to create a centre of excellence for customer service and one of the best workplace experiences in the industry. The Bulgaria hub will set the gold standard for service quality, responsiveness, and multilingual support, playing a pivotal role in supporting clients worldwide while fostering a culture of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom